Valuation: DNAPrint Genomics, Inc.

Market Cap 2.58M 2.23M 2.08M 1.91M 3.59M 245M 3.65M 24.44M 9.59M 123M 9.68M 9.47M 407M P/E 2005
-0.23x
P/E 2006 -0.27x
Enterprise Value 1.36M 1.18M 1.1M 1.01M 1.9M 130M 1.93M 12.93M 5.07M 65.06M 5.12M 5.01M 215M EV / Sales 2005
1.89x
EV / Sales 2006 1.06x
Free-Float
100%
Yield 2005 *
-
Yield 2006 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 0
0
Manager TitleAgeSince
Director of Finance/CFO - 23/12/2009
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.29K
+0.99%+1.78%+4.07%+16.73% 49.47B
+3.71%+9.40%+486.98%+592.14% 43.61B
+2.70%+1.57%+33.39%+8.85% 39.29B
+5.60%+10.21%+16.76%+85.72% 39.6B
+2.21%+6.75%+21.31%+53.37% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+37.75%+126.84% 16.49B
-0.11%+2.41%+6.24%+18.87% 14.01B
+0.75%+15.04%+78.59%+30.30% 12.77B
Average +1.90%+5.69%+85.64%+116.60% 26.45B
Weighted average by Cap. +2.54%+6.10%+104.25%+140.79%

Financials

2005 2006
Net sales 1.28M 1.1M 1.03M 945K 1.78M 121M 1.81M 12.09M 4.74M 60.84M 4.79M 4.68M 201M 2.43M 2.1M 1.97M 1.8M 3.39M 232M 3.44M 23.06M 9.05M 116M 9.14M 8.94M 384M
Net income -8.72M -7.54M -7.04M -6.46M -12.15M -830M -12.34M -82.6M -32.42M -416M -32.73M -32.01M -1.37B -12.35M -10.68M -9.97M -9.15M -17.21M -1.18B -17.48M -117M -45.93M -589M -46.37M -45.36M -1.95B
Net Debt -737K -637K -595K -546K -1.03M -70.12M -1.04M -6.98M -2.74M -35.14M -2.77M -2.71M -116M -1.21M -1.05M -981K -900K -1.69M -116M -1.72M -11.51M -4.52M -57.94M -4.56M -4.46M -192M
Logo DNAPrint Genomics, Inc.
DNAPrint genomics, Inc. is a development-stage pharmaceutical company. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The Company generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level.
Employees
25
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. DNAG Stock